Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

Pollak, 2014, Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment, Nat Med, 20, 591, 10.1038/nm.3596 DeCensi, 2014, Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial, Breast Cancer Res Treat, 148, 81, 10.1007/s10549-014-3141-1 Pollak, 2012, Investigating metformin for cancer prevention and treatment: the end of the beginning, Cancer Discov, 2, 778, 10.1158/2159-8290.CD-12-0263 Sadeghi, 2012, Metformin use is associated with better survival of diabetic patients with pancreatic cancer, Clin Cancer Res, 18, 2905, 10.1158/1078-0432.CCR-11-2994 Wang, 2014, Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis, Diabetes Res Clin Pract, 106, 19, 10.1016/j.diabres.2014.04.007 Suissa, 2012, Metformin and the risk of cancer: time-related biases in observational studies, Diabetes Care, 35, 2665, 10.2337/dc12-0788 Tsilidis, 2014, Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial, Diabetes Care, 37, 2522, 10.2337/dc14-0584 Andrzejewski, 2014, Metformin directly acts on mitochondria to alter cellular bioenergetics, Cancer Metab, 2, 12, 10.1186/2049-3002-2-12 Bridges, 2014, Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria, Biochem J, 462, 475, 10.1042/BJ20140620 Foretz, 2010, Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state, J Clin Invest, 120, 2355, 10.1172/JCI40671 Shaw, 2005, The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin, Science, 310, 1642, 10.1126/science.1120781 Cusi, 1996, Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus, J Clin Endocrinol Metab, 81, 4059 Pollak, 2008, Insulin and insulin-like growth factor signalling in neoplasia, Nat Rev Cancer, 8, 915, 10.1038/nrc2536 Fisher, 1996, Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors, J Surg Res, 63, 310, 10.1006/jsre.1996.0266 Weinberg, 2015, Targeting mitochondria metabolism for cancer therapy, Nat Chem Biol, 11, 9, 10.1038/nchembio.1712 Javeshghani, 2012, Carbon source and myc expression influence the antiproliferative actions of metformin, Cancer Res, 72, 6257, 10.1158/0008-5472.CAN-12-2907 Birsoy, 2014, Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides, Nature, 508, 108, 10.1038/nature13110 Gravel, 2014, Serine deprivation enhances antineoplastic activity of biguanides, Cancer Res, 74, 7521, 10.1158/0008-5472.CAN-14-2643-T Ming, 2014, Dose-dependent AMPK-dependent and independent mechanisms of berberine and metformin inhibition of mTORC1, ERK, DNA synthesis and proliferation in pancreatic cancer cells, PLoS One, 9, e114573, 10.1371/journal.pone.0114573 Viale, 2014, Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function, Nature, 514, 628, 10.1038/nature13611 Hochster, 2006, Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer, Cancer, 107, 676, 10.1002/cncr.22036 Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923 Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, 369, 1691, 10.1056/NEJMoa1304369 Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 25, 1960, 10.1200/JCO.2006.07.9525 Lau, 2014, Metformin and erlotinib synergize to inhibit basal breast cancer, Oncotarget, 5, 10503, 10.18632/oncotarget.2391 Morgillo, 2013, Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines, Clin Cancer Res, 19, 3508, 10.1158/1078-0432.CCR-12-2777 Christensen, 2011, The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c, Pharmacogenet Genomics, 21, 837, 10.1097/FPC.0b013e32834c0010 Tempero, 2011, Pancreatic cancer treatment and research: an international expert panel discussion, Ann Oncol, 22, 1500, 10.1093/annonc/mdq545 Pollak, 2012, Metformin and pancreatic cancer: a clue requiring investigation, Clin Cancer Res, 18, 2723, 10.1158/1078-0432.CCR-12-0694 Nies, 2011, Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy, Handb Exp Pharmacol, 201, 105, 10.1007/978-3-642-14541-4_3 Yuan, 2013, Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma, Proc Natl Acad Sci USA, 110, 18226, 10.1073/pnas.1317577110 Appleyard, 2012, Phenformin as prophylaxis and therapy in breast cancer xenografts, Br J Cancer, 106, 1117, 10.1038/bjc.2012.56 Pritchard, 2011, Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14, J Clin Oncol, 29, 3869, 10.1200/JCO.2010.33.7006 Fuchs, 2015, A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial, Ann Oncol, 26, 921, 10.1093/annonc/mdv027 Algire, 2011, Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo, Oncogene, 30, 1174, 10.1038/onc.2010.483 Maiuri, 2015, Essential role for oxidative phosphorylation in cancer progression, Cell Metab, 21, 11, 10.1016/j.cmet.2014.12.013